1. Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies
   David B Zhen et al, 2019, Journal of Oncology Pharmacy Practice CrossRef
2. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
   Aurélien Lambert et al, 2017, Therapeutic Advances in Gastroenterology CrossRef
3. Dose dependent slurred speech and laryngopharyngeal dysesthesia due to oxaliplatin
   Diana Varghese et al, 2022, Journal of Oncology Pharmacy Practice CrossRef
4. Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review
   Mariagrazia De Lisa et al, 2020, Oncology and Therapy CrossRef